Skip to main content

Table 2 Injection route, 99mTc activity, labelling efficiency, number and viability of the labelled-ePB-MSCs injected to each dog in the different studies

From: Scintigraphic tracking of 99mTechnetium-labelled equine peripheral blood-derived mesenchymal stem cells after intravenous, intramuscular, and subcutaneous injection in healthy dogs

Study Dog Injection route Injected 99mTc activity (mCi) Labelling efficiency (%) Number of MSCs Viability of MSCs (%)
1 1 IV 17.36 71.50 415,000 87.95
2 17.64 59.58 305,000 88.52
3 19.40 67.80 385,000 83.00
4 16.38 60.15 335,000 79.10
2 5 IM 18.45 72.78 465,000 90.32
6 19.05 73.21 775,000 95.48
7 24.04 77.83 695,000 93.53
8 15.00 53.65 775,000 95.48
5 SC 15.62 66.21 825,000 96.96
6 20.15 69.18 785,000 93.63
7 23.38 78.02 760,000 94.74
8 23.49 78.34 730,000 94.52
3 6 IV 19.56 80.65 1,810,000 95.58
7 27.85 83.04 1,950,000 97.44
8 21.37 83.82 1,610,000 93.17
  1. mCi millicurie, IV intravenous, IM intramuscular, SC subcutaneous